Literature DB >> 33661942

Isoalantolactone inhibits pancreatic cancer proliferation by regulation of PI3K and Wnt signal pathway.

Chaoxiong Zhang1,2,3, Lei Huang4, Jingyuan Xiong2, Linshen Xie1,2, Shi Ying2, You Jia2, Yuqin Yao1,2, Xuejiao Song2, Zhenguo Zeng3,5, Jialing Yuan6,7.   

Abstract

BACKGROUND/AIMS: Isoalantolactone (IATL) is one of multiple isomeric sesquiterpene lactones and is isolated from inula helenium. IATL has multiple functions such as antibacterial, antihelminthic and antiproliferative activities. IATL also inhibits pancreatic cancer proliferation and induces apoptosis by increasing ROS production. However, the detailed mechanism of IATL-mediated pancreatic cancer apoptosis remains largely unknown.
METHODS: In current study, pancreatic carcinoma cell lines (PANC-1, AsPC-1, BxPC-3) and a mouse xenograft model were used to determine the mechanism of IATL-mediated toxic effects.
RESULTS: IATL (20μM) inhibited pancreatic adenocarcinoma cell lines proliferation in a time-dependent way; while scratch assay showed that IATL significantly inhibited PANC-1 scratch closure (P<0.05); Invasion assays indicated that IATL significantly attenuated pancreatic adenocarcinoma cell lines invasion on matrigel. Signal analysis showed that IATL inhibited pancreatic adenocarcinoma cell proliferation by blocking EGF-PI3K-Skp2-Akt signal axis. Moreover, IATL induced pancreatic adenocarcinoma cell apoptosis by increasing cytosolic Caspase3 and Box expression. This apoptosis was mediated by inhibition of canonical wnt signal pathway. Finally, xenograft studies showed that IATL also significantly inhibited pancreatic adenocarcinoma cell proliferation and induced pancreatic adenocarcinoma cell apoptosis in vivo.
CONCLUSIONS: IATL inhibits pancreatic cancer proliferation and induces apoptosis on cellular and in vivo models. Signal pathway studies reveal that EGF-PI3K-Skp2-Akt signal axis and canonical wnt pathway are involved in IATL-mediated cellular proliferation inhibition and apoptosis. These studies indicate that IATL may provide a future potential therapy for pancreatic cancer.

Entities:  

Year:  2021        PMID: 33661942      PMCID: PMC7932101          DOI: 10.1371/journal.pone.0247752

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  47 in total

1.  Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer.

Authors:  Tulasigeri M Totiger; Supriya Srinivasan; Venkatakrishna R Jala; Purushottam Lamichhane; Austin R Dosch; Alexander A Gaidarski; Chandrashekhar Joshi; Shobith Rangappa; Jason Castellanos; Praveen Kumar Vemula; Xi Chen; Deukwoo Kwon; Nilesh Kashikar; Michael VanSaun; Nipun B Merchant; Nagaraj S Nagathihalli
Journal:  Mol Cancer Ther       Date:  2018-11-07       Impact factor: 6.261

2.  MiR-373-3p enhances the chemosensitivity of gemcitabine through cell cycle pathway by targeting CCND2 in pancreatic carcinoma cells.

Authors:  Wenjie Hu; Qilong Liu; Jie Pan; Zheng Sui
Journal:  Biomed Pharmacother       Date:  2018-06-19       Impact factor: 6.529

3.  Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  T Seufferlein; J B Bachet; E Van Cutsem; P Rougier
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

Review 4.  Therapeutic potency of Wnt signaling antagonists in the pathogenesis of prostate cancer, current status and perspectives.

Authors:  Mehran Pashirzad; Mojtaba Shafiee; Majid Khazaei; Hamid Fiuji; Mikhail Ryzhikov; Saman Soleimanpour; AmirReza Hesari; Amir Avan; Seyed Mahdi Hassanian
Journal:  J Cell Physiol       Date:  2018-09-07       Impact factor: 6.384

Review 5.  Pancreatic cancer: Stroma and its current and emerging targeted therapies.

Authors:  Janaiah Kota; Julie Hancock; Jason Kwon; Murray Korc
Journal:  Cancer Lett       Date:  2017-01-14       Impact factor: 8.679

6.  Effect of Wnt inhibitors in pancreatic cancer.

Authors:  Ilona Wall; Ingo G H Schmidt-Wolf
Journal:  Anticancer Res       Date:  2014-10       Impact factor: 2.480

Review 7.  Dkk1 involvement and its potential as a biomarker in pancreatic ductal adenocarcinoma.

Authors:  Eseosaserea Igbinigie; Fengbiao Guo; Shi-Wen Jiang; Cullen Kelley; Jinping Li
Journal:  Clin Chim Acta       Date:  2018-11-16       Impact factor: 3.786

Review 8.  Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer.

Authors:  Erkut Borazanci; Daniel D Von Hoff
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2014-05-31       Impact factor: 3.869

9.  Attenuation of murine acute lung injury by PF-573,228, an inhibitor of focal adhesion kinase.

Authors:  Paul A Lederer; Tingting Zhou; Weiguo Chen; Yulia Epshtein; Huashan Wang; Biji Mathew; Jeffrey R Jacobson
Journal:  Vascul Pharmacol       Date:  2018-06-30       Impact factor: 5.773

Review 10.  The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma.

Authors:  Balbina García-Reyes; Anna-Laura Kretz; Jan-Philipp Ruff; Silvia von Karstedt; Andreas Hillenbrand; Uwe Knippschild; Doris Henne-Bruns; Johannes Lemke
Journal:  Int J Mol Sci       Date:  2018-10-18       Impact factor: 5.923

View more
  5 in total

Review 1.  Sesquiterpene Lactones as Promising Candidates for Cancer Therapy: Focus on Pancreatic Cancer.

Authors:  Laura Cecilia Laurella; Nadia Talin Mirakian; Maria Noé Garcia; Daniel Héctor Grasso; Valeria Patricia Sülsen; Daniela Laura Papademetrio
Journal:  Molecules       Date:  2022-05-29       Impact factor: 4.927

2.  Isoalantolactone Induces Cell Cycle Arrest, Apoptosis and Autophagy in Colorectal Cancer Cells.

Authors:  Junkui Li; Peili Zhu; Yifei Chen; Shiqing Zhang; Zhu Zhang; Zhang Zhang; Ying Wang; Xiaoli Jiang; Kaili Lin; Wei Wu; Zhixian Mo; Stephen Cho Wing Sze; Ken Kin Lam Yung
Journal:  Front Pharmacol       Date:  2022-05-12       Impact factor: 5.988

Review 3.  Back to the Roots-An Overview of the Chemical Composition and Bioactivity of Selected Root-Essential Oils.

Authors:  Karin Lunz; Iris Stappen
Journal:  Molecules       Date:  2021-05-25       Impact factor: 4.411

4.  Target c-Myc to treat pancreatic cancer.

Authors:  Moein Ala
Journal:  Cancer Biol Ther       Date:  2022-01-03       Impact factor: 4.742

5.  PHGDH Inhibitor CBR-5884 Inhibits Epithelial Ovarian Cancer Progression via ROS/Wnt/β-Catenin Pathway and Plays a Synergistic Role with PARP Inhibitor Olaparib.

Authors:  Xiaocui Zhang; Meige Sun; Yisheng Jiao; Bei Lin; Qing Yang
Journal:  Oxid Med Cell Longev       Date:  2022-09-05       Impact factor: 7.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.